inebilizumab
MedImmune
['horizonnews']
today we announced the results of two post-hoc studies from the phase 3 trial for our neuromyelitis optica spectrum disorder (#nmosd) medicine that will be presented at the 38th congress of the annual meeting: #ectrims2022 
At Horizon, we believe science and compassion must work together to transform lives.